Astrazeneca Ab

Christian Tyrchan

Matthew Wd Perry

Antonios Nikitidis

Mickael Mogemark

Jens Petersen

Konstantinos Karabelas

Erik Ringberg

Magnus Munck Af Rosenschöld

Robert Rönn

Pavol Zlatoidsky

Grigorios Nikitidis

Petra Johannesson

Peter Nilsson

Peter Bold

Nils Pemberton

Rhona Cox

Carl Jonas Lindh

Hanna Birgitta Ellinor Andersson

Ulf Borjesson

Wesley Ralph Schaal

Matthew Perry

Ulf BÖRJESSON

Disclosed herein is the compound (S)-2-(1-cyclopropylethyl)-5-(4-methyl-2-((6-(2-oxopyrrolidin-1-yl)pyridin-2-yl)amino)thiazol-5-yl)-7-(methylsulfonyl)isoindolin-1-one of the following structure: and/or pharmaceutically acceptable salts and/or pharmaceutical compositions thereof, which inhibit phosphatidylinositol 3-kinase (PI3K) activity.

(S)-2-(1-cyclopropylethyl)-5-(4-methyl-2-((6-(2-oxopyrrolidin-1-yl)pyridin-2-yl)amino) thiazol-5-yl)-7-(methylsulfonyl)isoindolin-1-one as a phosphatidylinositol 3-kinase inhibitor

There are disclosed certain novel compounds (including pharmaceutically acceptable salts thereof), that inhibit phosphatidylinositol 3-kinase gamma (PI3K&#x3b4;) activity, to their utility in treating and/or preventing clinical conditions including respiratory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), to their use in therapy, to pharmaceutical compositions containing them and to processes for preparing such compounds.

Inhibitors of phosphatidylinositol 3-kinase gamma

There is provided compounds of formula I, wherein E, E, E, E, L, Y, Y, Y, Rand z have meanings provided in the description, and pharmaceutically-acceptable salts thereof, which compounds are useful in the treatment of diseases in which inhibition of leukotriene Csynthase is desired and/or required, and particularly in the treatment of respiratory diseases and inflammation.

Compounds and uses

Growing community of inventors

Mölndal, Sweden

Christian Tyrchan